Abstract: The current disclosure relates to methods of depositing transition metal on a substrate. The disclosure further relates to a transition metal layer, to a structure and to a device comprising a transition metal layer. In the method, transition metal is deposited on a substrate by a cyclical deposition process, and the method comprises providing a substrate in a reaction chamber, providing a transition metal precursor to the reaction chamber in a vapor phase and providing a reactant to the reaction chamber in a vapor phase to form transition metal on the substrate. The transition metal precursor comprises a transition metal from any of groups 4 to 6, and the reactant comprises a group 14 element selected from Si, Ge or Sn.

Abstract: There is provided a depot suitable for sustained-release drug delivery, said depot including a composite body comprising particles having at least one encapsulated active pharmaceutical ingredient The depot includes 50 to 95 wt % of the composite body particles, said composite body particles having 0.1 to 80 wt % of active pharmaceutical ingredient, and the active pharmaceutical ingredient is a non-steroidal anti-inflammatory drug. In addition, the composite body is formed of a silica hydrogel comprising the silica particles.

Abstract: According to an example aspect of the present invention, there is provided a cartridge for the delivery of medicine to mammals in veterinary applications comprising a non-woven cellulose tube having a closed end and an open end, wherein at least one cross-sectional area of the closed end is axially symmetric in relation to the longitudinal axis of the tube and the open end is plugged e.g. by folding or crushing the open end, or by inserting a cellulose cap, a disintegrating cap or a soluble cap.

Abstract: According to an example aspect of the present invention, there is provided a depot suitable for sustained-release drug delivery, said depot comprising a composite body comprising particles having at least one encapsulated active pharmaceutical ingredient The depot comprises 50 to 95 wt % of the composite body particles, said composite body particles comprising 0.1 to 80 wt % of active pharmaceutical ingredient, and the active pharmaceutical ingredient is a non-steroidal anti-inflammatory drug.